Valentina Lozano
Glaucoma Specialist · Culver City, CANPI 1659752079
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $30,761 of the $50,753 with a category attached, or 60.6%. 28 manufacturers reported payments, led by Alcon at 55.9% of the total. Reporting peaked in 2023 at $20,024 and has fallen 91.8% since, to $1,644 in 2025.
Across 236 payments — averaging $215.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$28K
- Alcon Research LLC$7K
- AbbVie$4K
- Ivantis, Inc$4K
- Sight Sciences, Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- plus $4K from 22 others
What the payments were for
- Consulting fees$30,76161%
- Speaking & faculty fees$8,73017%
- Travel & lodging$1,5713%
- Food & beverage$9,69119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 73 | $28,392 |
| Alcon Research LLC | 4 | $7,090 |
| AbbVie(2 entities) | 30 | $4,283 |
| Ivantis, Inc | 11 | $4,221 |
| Sight Sciences, Inc. | 37 | $1,760 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $1,156 |
| NEW World Medical,inc. | 6 | $844 |
| Aerie Pharmaceuticals, Inc. | 8 | $499 |
| Dompe US, Inc. | 11 | $411 |
| Glaukos Corporation | 5 | $387 |
| Carl Zeiss Meditec, Inc. | 2 | $333 |
| Carl Zeiss Meditec USA, Inc. | 1 | $165 |
| Tarsus Pharmaceuticals, Inc. | 5 | $130 |
| Rxsight Inc | 1 | $125 |
| Amgen(2 entities) | 6 | $122 |
| Mallinckrodt Enterprises LLC | 1 | $121 |
| Thea Pharma Inc. | 6 | $120 |
| Apellis Pharmaceuticals, Inc. | 3 | $103 |
| Oyster Point Pharma, Inc. | 4 | $91 |
| Bausch & Lomb Americas Inc. | 4 | $85 |
| Nova Eye, Inc. | 1 | $66 |
| Harrow Eye, LLC | 2 | $55 |
| Novartis | 3 | $50 |
| Akorn Operating Company LLC | 2 | $40 |
| Biotissue Holdings Inc. | 1 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Optos, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$33,206
- NGENUITY$1,400
- DURYSTA$1,100
- OMNI(R) SURGICAL SYSTEM (US)$930
- Tecnis Simplicity$900
- Clareon$520
- Rocklatan$414
- Rhopressa$414
- VERACITY SURGICAL$333
- Kahook Dual Blade$269
- Clearpath$269
- Ahmed Glaucoma Valve$269
- Streamline$269
- IOLMaster 700$184
- LUMERA$184
- QUATERA 700$184
- ARTEVO 800$149
- VisuMax$149
- AcrySof IQ PanOptix UV IOL$147
- ARGOS$146
How this compares
$50,753 in reported general payments places this provider in the 85th percentile of 64 glaucoma specialist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 119 | $56,103 |
| LumiganBimatoprost | 95 | $51,678 |
| XiidraLifitegrast | 52 | $40,215 |
| Alphagan PBrimonidine Tartrate | 65 | $30,410 |
| RocklatanNetarsudil Mesylat/Latanoprost | 68 | $27,969 |
| VyzultaLatanoprostene Bunod | 64 | $27,442 |
| CombiganBrimonidine Tartrate/Timolol | 63 | $22,399 |
| Latanoprost | 1,461 | $21,455 |
| Brimonidine Tartrate | 496 | $19,718 |
| RestasisCyclosporine | 21 | $18,650 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 692 | $16,743 |
| TafluprostTafluprost/Pf | 85 | $16,244 |
| Prednisolone Acetate | 457 | $13,455 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,333 |
| Cyclosporine | 30 | $11,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $4,283 | $123,137244 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $499 | $84,072187 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $85 | $79,990133 claims |
| Thea Pharma Inc.Iyuzeh | $120 | $4,09913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Culver City
- Daniel KrivoyCulver City$29K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.